Latest Hospitality News

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

EMVision Medical Devices is set to activate its sixth and final pivotal trial site at UCLA Health, advancing its emu™ brain scanner towards FDA submission. Meanwhile, the Continuous Innovation Study grows with the addition of Box Hill Hospital.

Tyro Payments Limited reported FY25 results with strong top-line growth and margin expansion, setting a confident outlook for FY26 backed by AI-driven efficiency and an expanded market.

Tyro Payments delivered solid FY25 results with a 10.6% rise in EBITDA and accelerated growth initiatives, including expansion into new $40 billion addressable markets and a pilot banking platform.

Tyro Payments reported modest transaction growth and a 10.6% rise in EBITDA for FY25, while preparing for a CEO change and expanding into new industry verticals.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Embelton Limited reports a notable decline in revenue and profit for FY2025 amid a challenging construction market, yet maintains its dividend payout, signaling cautious optimism.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

EVT Group has released an extensive valuation update on its diversified $2.3 billion property portfolio, spotlighting landmark Sydney CBD assets alongside a broad hospitality and entertainment footprint across Australia, New Zealand, and Germany.